ALXO
ALX Oncology Holdings Inc. NASDAQ Listed Jul 17, 2020$1.53
+5.52%
vs $1.45
Mkt Cap $82.1M
52w Low $0.41
51.2% of range
52w High $2.60
50d MA $1.76
200d MA $1.68
P/E (TTM)
-0.8x
EV/EBITDA
—
P/B
3.2x
Debt/Equity
0.2x
ROE
-391.4%
P/FCF
-1.0x
RSI (14)
30.90
ATR (14)
$0.12
Beta
0.50
50d MA
$1.76
200d MA
$1.68
Avg Volume
1.2M
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
323 Allerton Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | -0.38 | -0.42 | -10.5% | 2.11 | -4.3% | +0.5% | -2.4% | +5.8% | -2.7% | +3.8% | — |
| Nov 7, 2025 | AMC | -0.37 | -0.41 | -10.8% | 1.38 | -8.0% | -8.0% | +3.1% | -2.3% | -4.7% | +13.1% | — |
| Aug 12, 2025 | AMC | -0.46 | -0.49 | -6.5% | 0.62 | +0.8% | +7.4% | -0.8% | -1.6% | +50.7% | -8.4% | — |
| May 8, 2025 | AMC | -0.47 | -0.58 | -23.4% | 0.46 | +3.3% | -8.2% | +3.1% | +10.5% | -4.5% | -5.1% | — |
| Mar 6, 2025 | AMC | -0.72 | -0.55 | +23.6% | 1.31 | -4.6% | -19.1% | -15.7% | +8.9% | -1.4% | -13.3% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.58 | +25.6% | 1.51 | +2.6% | -4.0% | +2.1% | -9.5% | +0.0% | -0.7% | — |
| Aug 8, 2024 | AMC | -0.77 | -0.76 | +1.3% | 2.63 | +4.2% | -0.8% | -3.4% | +4.8% | -2.3% | +2.7% | — |
| May 9, 2024 | AMC | -0.87 | -0.71 | +18.4% | 16.95 | +3.2% | -4.4% | -3.7% | -2.8% | -1.0% | -2.4% | — |
| Mar 7, 2024 | AMC | -0.84 | -0.93 | -10.7% | 16.24 | -13.1% | -6.3% | -11.5% | -8.1% | -6.2% | -3.9% | — |
| Nov 13, 2023 | AMC | -0.86 | -1.24 | -44.2% | 8.43 | -8.9% | +4.7% | -0.7% | +1.8% | +6.4% | +3.2% | — |
| Aug 10, 2023 | AMC | -0.85 | -0.84 | +1.2% | 5.04 | -2.0% | +0.4% | -3.2% | -0.8% | -6.4% | +0.2% | — |
| May 11, 2023 | AMC | -0.84 | -0.58 | +31.0% | 6.27 | +3.5% | +4.1% | -1.1% | -6.6% | +4.6% | -4.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.18 | +2.3% | -4.2% | +5.4% | -6.0% | -2.0% | +5.1% |
| Feb 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.01 | $2.10 | +4.5% | +2.5% | -0.5% | +14.1% | +9.0% | -2.7% |
| May 21 | UBS | Maintains | Buy → Buy | — | $0.43 | $0.43 | +0.0% | -4.6% | +17.1% | -3.2% | -3.3% | -0.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.46 | $0.48 | +3.3% | -8.2% | +3.1% | +10.5% | -4.5% | -5.1% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.25 | -4.6% | -19.1% | -15.7% | +8.9% | -1.4% | -13.3% |
| Mar 7 | Stifel | Maintains | Hold → Hold | — | $1.31 | $1.25 | -4.6% | -19.1% | -15.7% | +8.9% | -1.4% | -13.3% |
| Mar 6 | Jefferies | Upgrade | Hold → Buy | — | $1.04 | $1.07 | +2.9% | +26.0% | -19.1% | -15.7% | +8.9% | -1.4% |
| Mar 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.04 | $1.07 | +2.9% | +26.0% | -19.1% | -15.7% | +8.9% | -1.4% |
| Jan 27 | UBS | Maintains | Buy → Buy | — | $1.52 | $1.45 | -4.6% | +2.6% | -1.9% | -4.6% | -10.3% | +11.5% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.63 | $1.55 | -4.9% | -6.7% | +2.6% | -1.9% | -4.6% | -10.3% |
| Jan 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.63 | $1.55 | -4.9% | -6.7% | +2.6% | -1.9% | -4.6% | -10.3% |
| Dec 19 | Jefferies | Downgrade | Buy → Hold | — | $1.84 | $1.78 | -3.3% | -19.6% | +9.5% | +15.4% | -2.1% | -7.7% |
| Dec 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.79 | $1.82 | +1.7% | +2.8% | -19.6% | +9.5% | +15.4% | -2.1% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.79 | $1.82 | +1.7% | +2.8% | -19.6% | +9.5% | +15.4% | -2.1% |
| Aug 16 | UBS | Maintains | Buy → Buy | — | $2.65 | $2.62 | -1.1% | -4.2% | +1.2% | -2.3% | -0.4% | -6.8% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.46 | -2.4% | +4.8% | -2.3% | +2.7% | -4.2% | +1.2% |
| Aug 9 | Stifel | Maintains | Hold → Hold | — | $2.63 | $2.74 | +4.2% | -0.8% | -3.4% | +4.8% | -2.3% | +2.7% |
| Aug 1 | Stifel | Maintains | Hold → Hold | — | $4.80 | $3.20 | -33.3% | -41.7% | +2.1% | -4.5% | +0.7% | -6.5% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.80 | $3.20 | -33.3% | -41.7% | +2.1% | -4.5% | +0.7% | -6.5% |
| Jun 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.01 | $8.86 | -1.7% | -3.8% | -1.3% | -0.4% | -1.1% | -4.6% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.34 | $12.02 | -2.6% | -2.4% | +11.0% | -2.6% | -1.1% | +12.4% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.21 | $15.58 | +2.4% | -11.5% | -8.1% | -6.2% | -3.9% | +1.3% |
| Mar 8 | Stifel | Downgrade | Buy → Hold | — | $16.24 | $14.12 | -13.1% | -6.3% | -11.5% | -8.1% | -6.2% | -3.9% |
| Mar 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.24 | $14.12 | -13.1% | -6.3% | -11.5% | -8.1% | -6.2% | -3.9% |
| Dec 8 | Jefferies | Upgrade | Hold → Buy | — | $9.25 | $10.22 | +10.5% | +32.5% | +2.0% | +2.5% | +3.8% | -0.8% |
| Nov 14 | Stifel | Maintains | Buy → Buy | — | $8.43 | $7.68 | -8.9% | +4.7% | -0.7% | +1.8% | +6.4% | +3.2% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.52 | $9.43 | -0.9% | -4.5% | +4.0% | -3.4% | +1.5% | -8.3% |
| Oct 4 | UBS | Maintains | Buy → Buy | — | $7.51 | $7.12 | -5.2% | -15.0% | +2.7% | +27.4% | -1.9% | +16.2% |
| Oct 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.51 | $7.12 | -5.2% | -15.0% | +2.7% | +27.4% | -1.9% | +16.2% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.81 | $8.09 | +68.2% | +56.1% | -15.0% | +2.7% | +27.4% | -1.9% |
| Sep 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.96 | $4.89 | -1.4% | +1.8% | +2.0% | -2.7% | +3.4% | -0.4% |
| Aug 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.06 | $5.02 | -0.8% | -3.2% | -0.8% | -6.4% | +0.2% | +3.3% |
| Aug 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.04 | $4.94 | -2.0% | +0.4% | -3.2% | -0.8% | -6.4% | +0.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.04 | $4.94 | -2.0% | +0.4% | -3.2% | -0.8% | -6.4% | +0.2% |
| Aug 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.04 | $4.94 | -2.0% | +0.4% | -3.2% | -0.8% | -6.4% | +0.2% |
| Jul 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.73 | $6.45 | -4.2% | -8.5% | -4.9% | +0.0% | -2.7% | +4.2% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.27 | $6.49 | +3.5% | +4.1% | -1.1% | -6.6% | +4.6% | -4.8% |
| Mar 15 | UBS | Maintains | Buy → Buy | — | $5.25 | $5.21 | -0.8% | -1.1% | -3.7% | -4.6% | -3.4% | +4.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.87 | $5.79 | -1.4% | -8.2% | +4.5% | -6.7% | -1.1% | -3.7% |
| Mar 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $5.87 | $5.79 | -1.4% | -8.2% | +4.5% | -6.7% | -1.1% | -3.7% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.50 | $12.63 | +1.0% | -0.6% | +1.5% | +1.4% | -3.2% | -6.3% |
| Aug 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $11.76 | $11.39 | -3.1% | +0.1% | +8.7% | +1.5% | +11.9% | +4.3% |
| Jun 6 | Stifel | Maintains | Buy → Buy | — | $7.60 | $7.72 | +1.6% | -5.9% | +8.4% | +3.0% | -2.5% | -12.8% |
| May 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.64 | $8.66 | +0.2% | +1.4% | -0.1% | -3.3% | -8.4% | +1.9% |
| Mar 1 | Stifel | Maintains | Buy → Buy | — | $18.12 | $17.52 | -3.3% | +0.1% | +4.0% | -7.6% | -4.5% | +3.1% |
| Dec 22 | Jefferies | Downgrade | Buy → Hold | — | $22.91 | $21.62 | -5.6% | -2.7% | +4.4% | -3.9% | -0.4% | -1.5% |
| Sep 30 | Stifel | Maintains | Buy → Buy | — | $73.36 | $75.03 | +2.3% | +0.7% | +0.7% | -4.4% | +4.0% | -7.2% |
| Apr 6 | UBS | Maintains | Buy → Buy | — | $75.23 | $76.75 | +2.0% | -0.8% | -7.3% | +4.3% | -11.7% | -9.1% |
| Feb 11 | Credit Suisse | Maintains | Outperform → Outperform | — | $80.42 | $83.34 | +3.6% | +0.6% | +1.0% | -0.3% | +4.3% | +1.1% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $82.18 | $85.75 | +4.3% | -2.1% | +0.6% | +1.0% | -0.3% | +4.3% |
No insider trades available.
8-K · 2.02
!! High
ALX Oncology Holdings Inc. -- 8-K 2.02: Earnings Results
ALX Oncology reported quarterly earnings results, with detailed financial performance metrics now available in their press release filing.
May 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions create uncertainty around strategic direction and operational continuity, potentially triggering stock volatility until investors assess the successor's qualifications and vision.
Apr 13
8-K
ALX Oncology Holdings Inc. -- 8-K Filing
ALX Oncology reported positive Phase 1b/2 biomarker data supporting its evorpacept and zanidatamab combination for HER2-positive breast cancer, advancing clinical development of its immunotherapy pipeline.
Feb 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 4,179,736 | $8M | New | Mar 2026 |
| 2 | Marshall Wace, Llp | 3,757,216 | $8M | Added | Mar 2026 |
| 3 | Vivo Capital, Llc | 3,184,713 | $6M | New | Mar 2026 |
| 4 | Millennium Management | 1,988,559 | $4M | Reduced | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 1,587,833 | $3M | Added | Mar 2026 |
| 6 | Susquehanna International Group, Llp | 1,328,907 | $3M | Added | Mar 2026 |
| 7 | Acadian Asset Management Llc | 1,101,025 | $2M | Reduced | Mar 2026 |
| 8 | Ensign Peak Advisors, Inc | 950,550 | $2M | New | Mar 2026 |
| 9 | Ubs Group Ag | 914,754 | $2M | Added | Mar 2026 |
| 10 | Renaissance Technologies Llc | 732,599 | $1M | Added | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 577,783 | $1M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 136,964 | $275K | Reduced | Mar 2026 |
| 13 | Qube Research & Technologies Ltd | 107,647 | $216K | New | Mar 2026 |
| 14 | Bank Of Nova Scotia | 105,858 | $212K | — | Mar 2026 |
| 15 | Jane Street Group, Llc | 185,961 | $210K | Added | Dec 2025 |
| 16 | Vanguard Portfolio Management Llc | 97,881 | $196K | New | Mar 2026 |
| 17 | Morgan Stanley | 167,514 | $189K | Reduced | Dec 2025 |
| 18 | Ieq Capital, Llc | 92,233 | $185K | — | Mar 2026 |
| 19 | Point72 Asset Management | 41,095 | $82K | Added | Mar 2026 |
| 20 | Hc Advisors, Llc | 22,900 | $46K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 10
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 189,414 | $400K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 77,665 | $164K | Feb 2026 |
| 3 | Ultra-Small Company Market Fund | 61,000 | $122K | Mar 2026 |
| 4 | Fidelity Series Total Market Index Fund | 49,321 | $104K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 26,897 | $57K | Feb 2026 |
| 6 | Small Cap Core Fund | 17,558 | $35K | Mar 2026 |
| 7 | Ultra-Small Company Fund | 15,072 | $30K | Mar 2026 |
| 8 | Avantis U.S. Small Cap Equity ETF | 4,191 | $9K | Feb 2026 |
| 9 | Avantis Total Equity Markets ETF | 1,632 | $3K | Feb 2026 |
| 10 | Guggenheim Active Allocation Fund | 105 | $222 | Feb 2026 |
Valuation
Market Cap
$82.1M
Enterprise Value
$37.3M
P/E (TTM)
-0.81x
Forward P/E
—
PEG Ratio
0.02x
P/B
3.16x
P/S
—
P/FCF
-0.97x
EV/EBITDA
—
Shares Out
53.7M
Financials (TTM)
Revenue
$0
Net Income
-$101.7M
EBITDA
-$100.8M
Free Cash Flow
-$84.4M
Op Cash Flow
-$84.1M
EPS Basic
$-1.90
EPS Diluted
$-1.90
EPS Forward
$-0.71
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$59.0M
Total Liab.
$33.1M
Total Equity
$26.0M
Cash
$44.8M
LT Debt
$0
Book Value/Sh
$0.48
Debt/Equity
0.20x
Current Ratio
2.07
Quick Ratio
2.07
Returns & Growth
ROE
-391.4%
ROA
-172.2%
ROIC
-254.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+26.4%
Price Returns
2W
-6.9%
1M
+11.8%
3M
-10.0%
6M
+38.7%
12M
+291.3%
Technicals
52W High
$2.60
52W Low
$0.41
50d MA
$1.76
200d MA
$1.68
RSI (14)
30.90
ATR (14)
$0.12
Beta
0.50
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$4.00
Low
$4.00
Median
$4.00
Data updated apr 24, 2026 5:37pm
· Source: financialmodelingprep.com